PMGC Holdings Inc. Reports $1.99 Million Revenue and $7.95 Million Net Loss for Six Months Ending June 30, 2026

PMGC Holdings Inc. reported significant financial developments in its latest 10-Q filing for the six months ending June 30, 2026. The company generated revenue of $1.99 million, a notable increase from zero revenue in the same period last year, attributed to the contributions from newly acquired subsidiaries, including Pacific Sun Packaging, AGA Precision Systems, SVM Machining, and A&B Aerospace. The cost of goods sold for the period was $1.37 million, resulting in a gross margin of $616,165, marking a substantial turnaround from the previous year when the company had no revenue-generating operations.

The company’s total operating expenses surged to $7.78 million, up from $2.22 million in the prior year, primarily due to increased consulting fees, office and administrative costs, and professional fees associated with the integration of new acquisitions. PMGC reported a net loss of $7.95 million for the six months, compared to a loss of $2.17 million in the same period of 2025. The increase in losses was largely driven by higher operational costs and interest expenses related to convertible debt.

In terms of strategic developments, PMGC completed two significant acquisitions during the reporting period: SVM Machining on February 2, 2026, and A&B Aerospace on May 11, 2026. These acquisitions are part of the company's strategy to expand its footprint in the aerospace and defense sectors. Additionally, PMGC formed a new subsidiary, NorthStrive Defense Tech, aimed at developing advanced defense technologies, including drone systems and autonomous solutions.

Operationally, PMGC's total assets increased to $36.56 million as of June 30, 2026, up from $12.87 million at the end of 2025. The company’s cash position improved significantly, with cash and cash equivalents rising to $18.14 million from $5.40 million. However, the company also reported an accumulated deficit of $28.93 million, reflecting ongoing challenges in achieving profitability. The company’s management indicated plans to raise additional capital and acquire cash-generating assets to support future operations and mitigate concerns regarding its ability to continue as a going concern.

Looking ahead, PMGC aims to leverage its recent acquisitions to drive revenue growth and enhance operational efficiency. The company plans to focus on clinical validation studies for its biotechnology assets, pursue additional acquisitions, and explore opportunities for out-licensing its technologies. Despite the current financial challenges, management remains optimistic about the company’s potential for growth and profitability in the coming years.